This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies. Find out more about how we use cookies and how to manage them by reading our cookie notice.

BRILIQUE™, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

*For physicians in 27 member states of the EU, Norway, Iceland and Liechtenstein.

Welcome to the BRILIQUE™ website for European physicians.*

This healthcare website is a resource for European physicians* with an interest in BRILIQUE™ for the treatment of Acute Coronary Syndromes.

*Physicians in 27 member states of EU and Norway, Iceland and Liechtenstein.

Welcome to the BRILIQUE™ website for European healthcare professionals*

This website is a European information resource intended for European healthcare professionals* with an interest in BRILIQUE™ and the treatment of acute coronary syndromes. Please choose which site you require.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of BRILIQUE™ may not be the same in different countries. Information on this site is based on the Summary of Product Characteristics (SPC) for BRILIQUE™ in the EU. Please refer to your local Prescribing Information for full details.

By clicking on the link below you are declaring and confirming that you are a healthcare professional.

Access to the BRILIQUE™ website for EU healthcare professionals.*

This website uses cookies to function and collect information on visitor activity. By continuing to use this website you acknowledge your consent to the placement and use of cookies. Further information on our cookie policy and how to delete them can be read within our Privacy Policy

Other BRILIQUE™ websites for healthcare professionals only:

Information for patients and members of the press:

PATIENTS: The website is intended for healthcare professionals only. If you are a patient, please click Patient Information Leaflet (PIL), which has been written for patients and provide information about taking or using this medicine. For Summary of Product Characteristics (SPC), please click here. Please contact healthcare professionals or product information in your local country for specific information about this product. For more information on AstraZeneca's products, please click here.

Press: If you are a member of the press, you should visit the AstraZeneca Press Office

*Physicians in the 27 member states of the EU and Norway, Iceland and Liechtenstein